查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968564

獸用單株抗體市場－全球產業規模、佔有率、趨勢、機會和預測：按動物類型、應用、最終用戶、地區和競爭對手分類，2021-2031年

Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type, By Application, End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球獸用單株抗體市場預計將從 2025 年的 9.2412 億美元成長到 2031 年的 22.0648 億美元，複合年成長率為 15.61%。

這些專門的生物療法旨在靶向疾病路徑中的特定蛋白質，例如受體和細胞激素，用於治療動物的皮膚炎、癌症和骨關節炎等疾病。推動該市場成長要素是寵物慢性病發病率的上升以及寵物照護方式日益趨向人類化。這促使人們對副作用比傳統藥物更少的、高度先進且具有物種特異性的治療方法的需求不斷成長。根據美國獸醫協會 (AVMA) 預測，到 2025 年，美國犬隻數量將達到 8,730 萬隻，這意味著這些療法的患者群體正在擴大。

市場概覽
預測期 2027-2031
市場規模：2025年 9.2412億美元
市場規模：2031年 22.0648億美元
複合年成長率：2026-2031年 15.61%
成長最快的細分市場 皮膚科
最大的市場 北美洲

儘管生物製藥市場成長潛力巨大，但由於其研發和生產高成本，仍面臨嚴峻的挑戰。不斷上漲的生產成本最終導致寵物飼主需要支付更高的價格，從而限制了低收入社區和價格敏感地區的寵物獲得和使用。因此，儘管單株抗體的臨床優勢顯而易見，但經濟負擔仍是其在全球市場滲透的主要障礙。

市場促進因素

動物慢性疾病和感染疾病率的上升是推動單株抗體應用的主要動力，尤其是在骨關節炎等疾病的長期疼痛管理方面。傳統的非類固醇消炎劑（NSAIDs）長期使用會產生副作用，而單株抗體透過中和特定蛋白，在提供鎮痛效果的同時，具有更高的安全性。這一轉變在碩騰公司（Zoetis Inc.）2025年2月發布的財報中得到了印證，該財報顯示其骨關節炎疼痛管理業務部門實現了80%的業務成長，這證實了獸醫越來越傾向於優先採用生物製藥療法治療老年寵物的慢性疾病。

同時，寵物健康保險的日益普及在維持市場成長方面發揮著至關重要的作用，它能夠抵消這些先進療法的高成本。由於單株抗體價格昂貴，保險覆蓋確保了患者堅持治療並獲得廣泛的治療機會。美國寵物用品協會 (APPA) 2025 年 3 月的數據顯示，飼主願意在醫療保健方面投入資金，數據顯示，2024 年美國寵物產業的支出將達到 1,520 億美元。此外，北美寵物健康保險協會 (NAPHIA) 2025 年 6 月的報告顯示，2024 年美國寵物健康保險的總保費收入將超過 47 億美元的歷史新高，這表明市場對高價值獸醫服務的強勁支持。

市場挑戰

生物製藥研發生產的高成本是限制全球獸用單株抗體市場擴張的主要經濟障礙。由於這些治療方法需要複雜的技術和生產過程，其高昂的價格往往會轉嫁給消費者。因此，臨床效用與實際可近性之間存在差距，獸醫常常不願意為經濟拮据的飼主開具有效但昂貴的治療方法。結果，許多潛在客戶被迫依賴價格較低的傳統藥物，導致這些先進生物製藥的市場佔有率下降。

這種價格敏感度直接影響寵物就診頻率和高價值治療方案的採用率。根據澳洲動物醫學會2025年的調查，30%的犬飼主22%的貓飼主表示，減少就診次數的主要原因是經濟負擔。這項數據凸顯了一個重要的摩擦點，即經濟限制阻礙了人們獲得醫療保健服務。只要這些治療方案對一般收入家庭來說仍然難以負擔，市場就難以將疾病發生率的上升轉化為永續的收入成長。

市場趨勢

市場正從骨關節炎和皮膚病領域向其他領域擴展，治療範圍也不斷擴大。尤其值得一提的是，針對感染疾病的單株抗體研發取得了顯著進展。研發人員正在檢驗能夠中和病毒威脅的生物製藥的有效性，為高致死性疾病提供標靶治療，作為支持性治療的替代方案。例如，在犬小病毒的治療方面，已經建立了既能控制症狀又能直接攻擊病毒本身的治療方法。 2024年10月，禮來動物保健公司（Elanco Animal Health）公佈的數據顯示，使用其專有的犬細小病毒單株抗體治療的幼犬存活率達到了93%，這表明在降低死亡率方面取得了顯著進展。

此外，隨著大型製藥企業尋求整合來自敏捷生物技術公司的新型生物製藥平台，策略授權協議和聯合開發夥伴關係正在增加。這些合作使市場領導能夠繞過藥物研發瓶頸，並獲得諸如延長半衰期等專有技術。一個典型的例子是，Dekra Pharmaceuticals 於 2024 年 7 月以高達 5.2 億美元的價格收購了 Invex，從而獲得了一系列用於治療伴侶動物慢性疾病的特異性單株抗體。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：獸用單株抗體的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 動物種類（狗，其他）
    • 依應用領域（皮膚科、疼痛管理、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美獸用單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲獸用單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區獸用單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲獸用單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美獸用單株抗體市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球獸用單株抗體市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim Animal Health GmbH
  • Merck & Co., Inc.
  • Virbac SA
  • Ceva Sante Animale SA
  • IDEXX Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Vetoquinol SA
  • Aratana Therapeutics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17566

The Global Monoclonal Antibodies In Veterinary Health Market is projected to expand from USD 924.12 Million in 2025 to USD 2206.48 Million by 2031, registering a CAGR of 15.61%. These specialized biologic therapies are engineered to target specific proteins, such as receptors or cytokines, within disease pathways to treat animal conditions like dermatitis, cancer, and osteoarthritis. The market is primarily driven by the increasing prevalence of chronic diseases in pets and the trend toward pet humanization, which fuels demand for advanced, species-specific treatments with fewer side effects than traditional drugs. As noted by the American Veterinary Medical Association, the U.S. dog population reached 87.3 million in 2025, highlighting a growing patient base for these therapeutics.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 924.12 Million
Market Size 2031USD 2206.48 Million
CAGR 2026-203115.61%
Fastest Growing SegmentDermatology
Largest MarketNorth America

Despite the strong potential for growth, the market encounters significant challenges due to the high costs associated with developing and manufacturing biologic drugs. These steep production expenses result in higher prices for pet owners, which restricts accessibility and adoption in lower-income demographics or price-sensitive regions. Consequently, while the clinical advantages of monoclonal antibodies are clear, the financial burden remains a major obstacle to achieving widespread global market penetration.

Market Driver

The rising incidence of chronic and infectious diseases in animals acts as a primary catalyst for the adoption of monoclonal antibodies, especially for long-term pain management in conditions like osteoarthritis. Unlike traditional NSAIDs, which can cause adverse effects over time, monoclonal antibodies neutralize specific proteins to provide pain relief with a better safety profile. This shift is highlighted by Zoetis Inc.'s February 2025 financial results, which reported an 80% operational growth in their osteoarthritis pain franchise, confirming that veterinarians are increasingly prioritizing biologic interventions for chronic ailments in aging pets.

Simultaneously, the increasing penetration of pet health insurance plays a crucial role in sustaining market growth by offsetting the high costs of these advanced treatments. Since monoclonal antibodies are premium products, insurance coverage ensures patient adherence and broader accessibility. The willingness of owners to spend on healthcare is reflected in American Pet Products Association data from March 2025, showing U.S. pet industry expenditures reached $152 billion in 2024. Additionally, the North American Pet Health Insurance Association reported in June 2025 that gross written premiums in the U.S. surpassed a record $4.7 billion in 2024, demonstrating strong financial support for high-value veterinary care.

Market Challenge

The elevated costs associated with developing and manufacturing biologic drugs create a substantial economic barrier that limits the expansion of the Global Monoclonal Antibodies In Veterinary Health Market. Because these therapies require complex engineering and production, the premium pricing is typically passed on to the consumer. This leads to a discrepancy between clinical availability and practical accessibility, as veterinarians are often hesitant to prescribe effective but expensive treatments to clients with limited funds. As a result, many potential customers depend on lower-cost conventional pharmaceuticals, reducing the market share for these advanced biologics.

This price sensitivity directly affects veterinary visit frequency and the uptake of high-value treatments. According to Animal Medicines Australia in 2025, 30% of dog owners and 22% of cat owners who reduced their veterinary visits cited affordability as the primary reason. This data underscores a critical friction point where economic constraints prevent access to necessary healthcare. As long as these treatments remain financially out of reach for average-income households, the market will struggle to convert rising disease prevalence into sustained revenue growth.

Market Trends

The market is expanding its therapeutic focus beyond osteoarthritis and dermatology, with a notable surge in monoclonal antibodies targeting infectious diseases. Developers are validating biologics that neutralize viral threats, providing targeted alternatives to supportive care for high-mortality conditions. For example, treatments for canine parvovirus now combat the virus directly rather than just managing symptoms. In October 2024, Elanco Animal Health released data showing that 93% of puppies treated with their Canine Parvovirus Monoclonal Antibody survived, marking a significant improvement in reducing mortality rates.

In addition, strategic licensing and co-development partnerships are increasing as major pharmaceutical companies seek to integrate novel biologic platforms from agile biotech firms. These collaborations allow market leaders to bypass discovery bottlenecks and access proprietary technologies, such as half-life extension. A key example occurred in July 2024, when Dechra Pharmaceuticals agreed to acquire Invetx for up to $520 million, thereby gaining access to a pipeline of specialized monoclonal antibodies for chronic diseases in companion animals.

Key Market Players

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim Animal Health GmbH
  • Merck & Co., Inc.
  • Virbac S.A.
  • Ceva Sante Animale S.A.
  • IDEXX Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Vetoquinol S.A.
  • Aratana Therapeutics, Inc.

Report Scope

In this report, the Global Monoclonal Antibodies In Veterinary Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monoclonal Antibodies In Veterinary Health Market, By Animal Type

  • Dogs
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Application

  • Dermatology
  • Pain
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibodies In Veterinary Health Market.

Available Customizations:

Global Monoclonal Antibodies In Veterinary Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibodies In Veterinary Health Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Dogs, Others)
    • 5.2.2. By Application (Dermatology, Pain, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Application

7. Europe Monoclonal Antibodies In Veterinary Health Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Monoclonal Antibodies In Veterinary Health Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Monoclonal Antibodies In Veterinary Health Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Application

10. South America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Monoclonal Antibodies In Veterinary Health Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Elanco Animal Health Incorporated
  • 15.3. Boehringer Ingelheim Animal Health GmbH
  • 15.4. Merck & Co., Inc.
  • 15.5. Virbac S.A.
  • 15.6. Ceva Sante Animale S.A.
  • 15.7. IDEXX Laboratories, Inc.
  • 15.8. Thermo Fisher Scientific Inc.
  • 15.9. Vetoquinol S.A.
  • 15.10. Aratana Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer